1-3 of 3
James Woodworth
Close
Sort by
Journal Articles

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Clinical Trials & Observations
John C. Byrd, Thomas J. Kipps, Ian W. Flinn, Januaro Castro, Thomas S. Lin, William Wierda, Nyla Heerema, James Woodworth, Steve Hughes, Shabnam Tangri, Sarah Harris, Dee Wynne, Arturo Molina, Bryan Leigh, Susan O'Brien
Journal: Blood
Blood (2010) 115 (3): 489–495.
https://doi.org/10.1182/blood-2009-08-237727
Published: 2010
Journal Articles

Anti-Drug Antibody Responses to Lumiliximab Are Not Detected in Relapsed Refractory CLL Patients Treated with Lumiliximab in Combination with FCR in a Phase 1/II Study

Julie Ranuio, Annalee Estrellado, Sarah Harris, Megan Shannon, Meena Subramanyam, Steve Hughes, James Woodworth, Shabnam Tangri
Journal: Blood
Blood (2008) 112 (11): 4210.
https://doi.org/10.1182/blood.V112.11.4210.4210
Published: 2008
Journal Articles

Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia.

James Woodworth, Ph.D., Bryan R. Leigh, M.D., Susan O’Brien, M.D., Ian Flinn, M.D., Thomas J. Kipps, M.D., Mark A. Weiss, M.D., Kanti Rai, M.D., Aron Thall, Ph.D., Dee Wynne, R.N., John C. Byrd, M.D.
Journal: Blood
Blood (2004) 104 (11): 4831.
https://doi.org/10.1182/blood.V104.11.4831.4831
Published: 2004